BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma
Pigment Cell & Melanoma Research · 2025-05 · 38 (3)
DOI: 10.1111/pcmr.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 29.04.2025. Verfasst von C J Cunanan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Ubiquitin Thiolesterase, Tumor Suppressor Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, NCI NIH HHS, Drexel University Department of Pharmacology and Physiology.
Abstract (Originalsprache)
Uveal melanoma (UM) is an aggressive intraocular malignancy. Despite effective control of primary tumors, ~50% of UM patients develop metastases, with the liver being the predominant secondary site. BAP1 deficiency, present in ~80% of metastatic UM cases, is strongly associated with increased metastatic risk and poor prognosis. In silico analysis of UM patient samples suggests that reduced BAP1 is linked to enhanced expression of genes involved in fatty acid processing; therefore, we hypothesize that BAP1 deficiency primes UM cells for survival in the hepatic microenvironment by enhancing lipid tolerance and oxidative stress responses. Our findings demonstrate BAP1‐mutant UM resist lipotoxicity, whereas BAP1‐competent UM exhibit sensitivity due to lipid peroxide accumulation—a hallmark of ferroptotic‐like stress, and a response that can be mitigated by ferroptosis inhibition. Using an ex vivo liver slice model, we found that disrupting lipid metabolism with atorvastatin, an HMG‐CoA reductase inhibitor, reduced tumor burden of BAP1‐mutant UM. Moreover, we demonstrate a positive correlation between BAP1 and an epigenetic regulator of lipid homeostasis, ASXL2. Notably, ASXL2 depletion in BAP1‐competent UM phenocopies the lipotoxicity resistance observed in BAP1‐mutant UM—an effect that may be mediated by altered PPAR expression. This study reveals a novel mechanism linking BAP1 expression to lipid sensitivity via ASXL2, providing insights into liver tropism and potential therapeutic avenues for metastatic uveal melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, USA.
- Department of Microbiology & Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: J L Hope
Förderung
- U.S. Department of Defense
- NCI NIH HHS
- Drexel University Department of Pharmacology and Physiology
- NIDA NIH HHS
- NIH HHS
- NIMH NIH HHS
- Comprehensive NeuroHIV Center Developmental Research and Mentoring Core
- Sidney Kimmel Comprehensive Cancer Center
Zitieren
APA
Cunanan, C. J., Amirfallah, A., Sanders, A. B., Gallant, K. C., Cavallo, M. R., Homer, E. A., El Naggar, O. S., Farnan, J. K., Romano, G., Hope, J. L., Jackson, J. G., & Hartsough, E. J. (2025). BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma. Pigment Cell & Melanoma Research, 38(3). https://doi.org/10.1111/pcmr.70021
Vancouver
Cunanan CJ, Amirfallah A, Sanders AB, Gallant KC, Cavallo MR, Homer EA, et al. BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma. Pigment Cell & Melanoma Research. 2025;38(3). doi:10.1111/pcmr.70021
BibTeX
@article{Cunanan2025,
author = {Cunanan, C J and Amirfallah, A and Sanders, A B and Gallant, K C and Cavallo, M R and Homer, E A and El Naggar, O S and Farnan, J K and Romano, G and Hope, J L and Jackson, J G and Hartsough, E J},
title = {BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma},
journal = {Pigment Cell & Melanoma Research},
year = {2025},
volume = {38},
number = {3},
doi = {10.1111/pcmr.70021}
}
EUVIMED